Immunovant (IMVT) AI Stock Analysis

• Market Cap: $4.23B
• Dividend Yield: N/A
• Average Volume (3M): 1.69M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.02
• Revenue Growth: N/A
• EPS Growth: -27.70%
• Country: US
• Employees: 362
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.73
• Shares Outstanding: 175,276,520
• 10 Day Avg. Volume: 1,078,186
• 30 Day Avg. Volume: 1,690,679
• PEG Ratio: -0.14
• Price to Book (P/B): 3.66
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -6.88
• Enterprise Value/Market Cap: 0.54
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -4.68
• 1Y Price Target: $39.63
• Price Target Upside: 74.20% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8
• EPS Forecast (FY): -2.87
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: ―

Immunovant's stock score is primarily impacted by substantial financial weaknesses, including ongoing losses and cash flow issues. Technical indicators are bearish, further weighing on the stock's attractiveness. However, recent positive clinical trial results and leadership changes provide some optimism, potentially strengthening the company's pipeline and long-term prospects.

Positive Factors

Leadership Change

The appointment of a new CEO and CFO marks a strategic shift, potentially enhancing operational effectiveness and strategic direction, which could improve long-term market positioning.

Clinical Trial Success

Successful clinical trials demonstrate the efficacy of Immunovant's therapies, potentially leading to future regulatory approvals and market entry, strengthening the company's pipeline.

Strategic Expansion

Expanding into new indications with promising clinical data could diversify revenue streams and enhance competitive positioning in the autoimmune disease market.

Negative Factors

Negative Cash Flow

Persistent negative cash flow indicates reliance on external funding, which could hinder long-term sustainability and operational independence.

Ongoing Losses

Continued financial losses raise questions about the company's ability to achieve profitability, impacting its long-term viability and investor confidence.

Lack of Revenue

The absence of revenue growth highlights challenges in commercializing products, which is critical for transitioning from development to a sustainable business model.

Immunovant Business Overview & Revenue Model

Company Description

Immunovant, Inc. (IMVT) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with autoimmune diseases. The company is dedicated to creating transformative treatments by utilizing its expertise in immunology. Its lead product candidate, batoclimab, is a monoclonal antibody targeting the neonatal Fc receptor (FcRn), which is being developed for the treatment of various autoimmune disorders.

How the Company Makes Money

Immunovant generates potential revenue primarily through the development and commercialization of its drug candidates. The company's revenue model hinges on the successful clinical development, regulatory approval, and eventual marketing of its lead product candidate, batoclimab. Immunovant may earn revenue through partnerships, collaborations, or licensing agreements with other pharmaceutical companies, which can provide upfront payments, milestone payments, and royalties based on product sales. Additionally, funding from investors and strategic partnerships plays a crucial role in supporting its research and development activities until the drugs reach the market.

Immunovant Financial Statement Overview

Summary

Immunovant is facing substantial financial challenges, characterized by persistent losses and negative cash flows. While the company maintains a solid equity position and low leverage, the lack of revenue and profitability raises questions about its long-term viability. Investors should be cautious and consider the company's strategy for achieving sustainable growth and profitability.

Income Statement

Immunovant shows significant financial challenges, with negative EBIT, EBITDA, and net income margins in the TTM period. The gross profit margin is positive, but revenue growth is non-existent due to the lack of revenue in previous periods. This indicates an ongoing reliance on funding rather than operational success.

Balance Sheet

The balance sheet reflects a strong equity position with a low debt-to-equity ratio, indicating minimal leverage risk. However, the return on equity is negative due to substantial net losses, which is a concern for investors looking for profitability.

Cash Flow

Cash flow from operations is negative, which raises concerns about the company's ability to sustain operations without external financing. Despite this, the company has managed to maintain a positive cash balance, likely due to financing activities. The free cash flow to net income ratio is not favorable, reflecting cash burn issues.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	-486.69M	-437.77M	-269.98M	-208.08M	-155.91M	-108.05M
Net Income	-464.69M	-413.84M	-259.34M	-210.96M	-156.73M	-107.43M
Balance Sheet
Total Assets	582.96M	776.22M	666.71M	405.84M	515.56M	412.49M
Cash, Cash Equivalents and Short-Term Investments	521.87M	713.97M	635.37M	376.53M	493.82M	400.15M
Total Debt	0.00	98.00K	138.00K	1.22M	2.36M	3.42M
Total Liabilities	63.25M	68.78M	48.95M	43.34M	45.74M	21.01M
Stockholders Equity	519.71M	707.45M	617.76M	362.49M	469.82M	391.48M
Cash Flow
Free Cash Flow	-431.33M	-376.63M	-214.59M	-188.39M	-106.37M	-83.54M
Operating Cash Flow	-430.95M	-375.87M	-214.23M	-188.19M	-106.11M	-83.33M
Investing Cash Flow	-381.00K	-759.00K	-360.00K	-197.00K	-254.00K	-210.00K
Financing Cash Flow	480.59M	454.49M	472.43M	70.89M	200.13M	383.11M

Immunovant Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 22.75
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMVT, the sentiment is Neutral. The current price of 22.75 is below the 20-day moving average (MA) of 23.46, above the 50-day MA of 20.20, and above the 200-day MA of 17.39, indicating a neutral trend. The MACD of 0.81 indicates Positive momentum. The RSI at 51.94 is Neutral, neither overbought nor oversold. The STOCH value of 58.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IMVT.

Immunovant Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PTGX	70 Neutral	$5.63B	142.09	7.80%	―	-35.39%	-72.97%
CRNX	65 Neutral	$4.32B	―	-44.42%	―	―	-21.96%
KYMR	54 Neutral	$4.81B	―	-32.09%	―	-50.05%	-54.47%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MIRM	51 Neutral	$3.75B	―	-15.81%	―	53.66%	58.63%
IMVT	45 Neutral	$4.23B	―	-95.93%	―	―	-27.70%
MLTX	41 Neutral	$945.70M	―	-54.17%	―	―	-157.74%

Immunovant Corporate Events

Immunovant Announces New CEO Amid Strategic Shift

Immunovant announced significant leadership changes effective April 2025, with Eric Venker appointed as CEO and Tiago Girao as CFO, as part of a strategic transition with Roivant Sciences increasing its operational involvement. The company is expanding its development of IMVT-1402 into new indications, Sjögren’s Disease and Cutaneous Lupus Erythematosus, with promising clinical trial data suggesting potential best-in-class efficacy, which could significantly impact its market positioning and stakeholder interests.

Spark’s Take on IMVT Stock

According to Spark, TipRanks’ AI Analyst, IMVT is a Neutral.

Immunovant’s stock score is primarily impacted by substantial financial weaknesses, including ongoing losses and cash flow issues. Technical indicators are bearish, further weighing on the stock’s attractiveness. However, recent positive clinical trial results provide some optimism, potentially strengthening the company’s pipeline and long-term prospects.

To see Spark’s full report on IMVT stock, click here.

Immunovant Announces Positive Phase 3 Study Results

On March 19, 2025, Immunovant announced positive results from its Phase 3 study of batoclimab for myasthenia gravis (MG) and initial results from its Phase 2b study for chronic inflammatory demyelinating polyneuropathy (CIDP). The MG study met its primary endpoint with significant improvements in the MG-ADL score, while the CIDP study showed promising improvements in disability scores. These results suggest deeper IgG reductions correlate with better clinical outcomes, supporting the potential of Immunovant’s therapies to address unmet needs in autoimmune conditions. Immunovant plans to focus on its lead asset IMVT-1402 for future studies, rather than seeking immediate regulatory approval for batoclimab.